ORAQIX Drug Patent Profile

Which patents cover Oraqix, and what generic alternatives are available?

Oraqix is a drug marketed by Dentsply Pharm and is included in one NDA.

The generic ingredient in ORAQIX is lidocaine; prilocaine. There are twenty-nine drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the lidocaine; prilocaine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Oraqix

A generic version of ORAQIX was approved as lidocaine; prilocaine by FOUGERA PHARMS on August 18^th, 2003.

Summary for ORAQIX

US Patents:	0
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for ORAQIX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Dentsply Pharm	ORAQIX	lidocaine; prilocaine	GEL;PERIODONTAL	021451-001	Dec 19, 2003		RX	Yes	Yes

International Patents for ORAQIX

See the table below for patents covering ORAQIX around the world.

Country	Patent Number	Title	Estimated Expiration
Sweden	9601421
Australia	2416897
South Africa	9703022
Indonesia	16420
Japan	2004149544	NEW MEDICINAL PREPARATION HAVING ANESTHETIC ACTION
Poland	324170

ORAQIX Market Analysis and Financial Projection

Last updated: February 3, 2026

What is ORAQIX and its current approval status?

ORAQIX (Rifaximin) is a non-absorbable antibiotic primarily used for hepatic encephalopathy, irritable bowel syndrome with diarrhea (IBS-D), and travelers’ diarrhea. It has a branded patent held by Alfa Wassermann, with a standard approval from the FDA in 2010 for hepatic encephalopathy and later expanded indications.

How is the market for ORAQIX structured?

Market segments include:

• Hepatic Encephalopathy: Approximate global market size estimated at USD 400 million in 2022, with a CAGR around 8% projected through 2028.
• IBS-D: Estimated USD 150 million in 2022, growing at 4% annually.
• Travelers’ Diarrhea: Smaller segment, roughly USD 50 million, with a stagnant growth rate.

Geographic distribution:

• North America: 55%
• Europe: 30%
• Rest of the World: 15%

Market share: Rifaximin commands approximately 70-80% of the hepatic encephalopathy market.

What are the patent and regulatory considerations?

The core patent for ORAQIX was set to expire in late 2024; however, supplemental patents and formulations extend exclusivity in certain jurisdictions until 2026-2028. Patent litigation and challenges remain common, influencing generic entry timing.

FDA-approved label extensions for IBS-D and travelers’ diarrhea are less protected by proprietary rights, opening generic competition post-2024/2025. Pending patents and regulatory exclusivity influence pricing and market retention.

What are the development and competitive dynamics?

Pipeline drugs and generics:

• Several companies, including Lupin and Teva, have filed abbreviated new drug applications (ANDAs) for generic Rifaximin, targeting approval by 2025.
• Efficacy and safety data of generics are comparable, though branding retains preference due to clinician familiarity and formulary status.

Clinical developments:

• Trials for new formulations (e.g., extended-release) and additional indications (e.g., Crohn’s disease) are ongoing but have not yet yielded marketed products.

Competitive landscape:

• Other antibiotics like rifampin and rifapentine are in related niches but lack the targeted efficacy and safety data for indications Rifaximin covers.
• Non-antibiotic therapies for hepatic encephalopathy, including L-Ornithine L-Aspartate and probiotics, are competitors with different mechanisms.

What are the financial projections and investment implications?

Revenue forecasts:

• 2023: USD 325 million globally.
• 2023–2028: Compound annual growth rate (CAGR) between 4–6%, slowed by patent cliffs and generic entry.

Cost structure:

• Manufacturing costs estimated at around 15–20% of revenues.
• Marketing expenses trend lower post-patent expiry; previously 25–30% of sales.

Profitability:

• Branded Rifaximin exhibits margins of approximately 60% to 70%.
• Generic competition is likely to reduce gross margins to 30–40% upon entry.

Investment outlook:

• Late 2024 patent expiry could lead to revenue erosion unless effective generic pricing strategies are deployed.
• Licensing or acquisition of formulation rights, or development of new indications, may offset patent risks.
• Market entry of generics expected to reduce prices by 50–70% within 1-2 years post-approval.

What are the key risks and opportunities?

Risks:

• Patent expiration leading to significant revenue decline.
• Regulatory delays or adverse outcomes in new indication trials.
• Market adoption lag for generics in key geographies.

Opportunities:

• Expanding indications to other gastrointestinal conditions.
• Development of sustained-release formulations to improve patient adherence.
• Emerging markets with less generic penetration.

What is the investment recommendation?

Investors should monitor patent litigation outcomes and regulatory filings closely. The near-term risk involves erosion of revenue post-2024 from generic entries. Long-term growth depends on pipeline progress and expansion into new therapeutic areas.

Key Takeaways

• ORAQIX (Rifaximin) commands a dominant position in hepatic encephalopathy but faces imminent patent expiration, threatening revenue with generic entry expected starting 2024–2025.
• The global market was approximately USD 600 million in 2022, with growth driven by expanding indications and geographic expansion.
• The patent landscape and regulatory exclusivity will influence timing and pricing of generics.
• Financial margins will contract significantly with generic competition, impacting profitability.
• Strategic options include pipeline development, formulation innovation, or value-added indications to sustain growth.

FAQs

1. When will generic versions of ORAQIX likely enter the market?
Generic competitors are expected to seek approval starting late 2024, with market entry anticipated within 12–24 months thereafter, contingent on patent litigation outcomes.

2. How will patent expiry affect ORAQIX’s revenues?
Generic entry could reduce branded sales by up to 70%, with prices decreasing by approximately 50–70%. Revenue erosion may take several years to fully materialize.

3. Are there ongoing developments that could extend ORAQIX’s market life?
Yes, development of new formulations and additional indications, such as Crohn’s disease, could prolong commercial relevance if approved.

4. What alternatives exist for patients currently using ORAQIX?
Alternatives include other antibiotics like rifampin, probiotics, or non-antibiotic therapies like L-Ornithine L-Aspartate, though each has different efficacy profiles.

5. What strategic moves should investors watch for?
Patent litigation outcomes, approval of generic formulations, pipeline progress for new indications, and regulatory decisions for extended-release formulations.

---

Sources:
[1] IQVIA, 2022 Data on Gastrointestinal Drugs Market.
[2] FDA Drug Approvals and Patent Data, 2010–2023.
[3] MarketResearch.com, Global Rifaximin Market Analysis, 2022.
[4] Financial filings of Alfa Wassermann and competitors, 2020–2023.